Repatha Cost in Delaware 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Repatha Actually Cost in Delaware in 2026?

The Amgen wholesale acquisition cost for Repatha sits at approximately $580 per month, and that figure is consistent across Delaware retail chains in 2026. Cash-pay patients without any assistance program face that full amount. With the Amgen Repatha SupportPlus copay card, eligible commercially insured patients can reduce their monthly out-of-pocket cost to as little as $0, subject to an annual maximum benefit [1]. Medicare and Medicaid beneficiaries are not eligible for manufacturer copay cards under federal anti-kickback rules, which means their net cost depends entirely on plan formulary placement and cost-sharing structure.

The distinction between "list price" and "net price" matters. Pharmacy benefit managers negotiate significant rebates from Amgen, so the price a Delaware insurer actually pays is substantially below $580. Those savings, however, do not always pass through to the patient at the pharmacy counter unless the plan uses a copay-accumulator-free model or passes rebates to plan members. Delaware residents enrolled in high-deductible health plans often pay the full list price until the deductible clears, which can mean several months of $580 charges early in the year [2].

Across the Delaware ZIP codes HealthRX tracks, the average out-of-pocket cost for commercially insured patients using the Amgen copay card in 2026 is well under $50 per month. Patients without insurance or without access to assistance programs pay closer to the full list price.

How Delaware Medicaid Covers Repatha

Delaware Medicaid covers evolocumab, but the coverage is not automatic. Prior authorization (PA) is required. The PA criteria align with the 2022 ACC/AHA cholesterol guideline recommendations: patients must have either heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD), and they must have tried and failed or been intolerant to maximally tolerated statin therapy, typically with documentation of at least one statin trial [3].

The guideline language is specific: "For patients with clinical ASCVD in whom LDL-C remains 70 mg/dL or higher despite maximally tolerated statin therapy and ezetimibe, it is reasonable to add a PCSK9 inhibitor" [4]. Delaware Medicaid follows this hierarchy closely in its PA criteria, so prescribers submitting a PA should document LDL-C values before and after statin therapy, any documented statin intolerance with muscle enzyme data, and the current LDL-C level that justifies escalation.

Once approved, Delaware Medicaid PA authorizations for Repatha are typically granted for 12 months and require renewal. Denials can be appealed; clinical documentation of a cardiac event, genetic testing confirming FH, or specialist notes from a cardiologist or endocrinologist tend to strengthen an appeal [5]. Delaware does not impose a quantity limit beyond the FDA-labeled dosing schedule, so both the 140 mg biweekly and 420 mg monthly regimens are covered when the PA is approved.

Repatha Coverage Under Commercial Insurance in Delaware

Most major commercial insurers operating in Delaware, including Highmark Blue Cross Blue Shield of Delaware, Aetna, Cigna, and United Healthcare, place Repatha on Tier 3 or Tier 4 of their formularies. That tier placement matters because it determines the copay or coinsurance percentage before the Amgen savings card applies.

Prior authorization requirements are nearly universal across commercial plans in Delaware. Step-therapy requirements are also common: a plan may require documentation that the patient tried a statin plus ezetimibe before approving a PCSK9 inhibitor. The ACC/AHA 2022 guideline supports this sequence, noting that "the addition of ezetimibe to maximally tolerated statin therapy can reduce LDL-C by an additional 15 to 20 percent" before escalating to a PCSK9 inhibitor [4].

For patients whose commercial plan approves Repatha, the Amgen SupportPlus copay card covers the remaining out-of-pocket cost up to the card's annual maximum, which Amgen has set at $7,200 per calendar year for 2026 [1]. Patients should enroll in the card before the first fill, not after, because retroactive application is generally not allowed. The enrollment process is online at Amgen's patient support portal and takes roughly 10 minutes.

Delaware insurance plans sold on the state exchange under the Affordable Care Act must cover FDA-approved drugs for ASCVD management, but formulary tier and PA requirements still apply [6]. Patients who feel their PA denial was improper have the right to an external independent review under Delaware Insurance Code, and the Delaware Department of Insurance handles complaints at no cost to the patient [7].

Medicare Part D and Repatha in Delaware

Medicare Part D covers evolocumab under most plans available to Delaware beneficiaries, but the coverage tier and cost-sharing vary by plan. In 2026, the Inflation Reduction Act drug price negotiation provisions and the redesigned Part D benefit structure change the math for high-cost medications. The new Part D out-of-pocket cap of $2,000 per year (effective January 2025, phased implementation) provides meaningful protection for patients who previously spent far more annually on drugs like Repatha [8].

Under the redesigned 2025 and 2026 Part D structure, once a beneficiary's out-of-pocket spending reaches $2 to 000 in a calendar year, all covered drugs cost $0 for the rest of the year [8]. For a patient paying, say, $150 per month in Part D cost-sharing for Repatha, the $2,000 cap would be reached by roughly the 13th month. In practice, most Delaware Part D beneficiaries on Repatha hit the cap before the end of the year if Repatha is their primary high-cost drug.

Medicare Advantage (Part C) plans in Delaware may have different formulary placements than standalone Part D plans. Patients should use the Medicare Plan Finder tool each October during open enrollment to compare actual cost-sharing for Repatha across available plans in their ZIP code [9].

Amgen's copay card does not apply to Medicare beneficiaries. However, Amgen's separate patient assistance program, Repatha SupportPlus, offers free drug for Medicare beneficiaries who meet income criteria. The income threshold for free drug is typically at or below 600% of the federal poverty level, though Amgen adjusts program terms annually [1].

Compounded Evolocumab in Delaware: What Is Legal

503A compounding pharmacies in Delaware may legally prepare evolocumab for individual patients under a valid prescription from a licensed prescriber. This is distinct from 503B outsourcing facilities, which produce drug in bulk for distribution. A 503A pharmacy compounds for a specific named patient based on a prescriber's order [10].

The FDA has not placed evolocumab on its list of drugs that are essentially a copy of a commercially available product in a way that would prohibit 503A compounding, and no federal prohibition on PCSK9 inhibitor compounding was in effect as of mid-2025. Delaware Board of Pharmacy rules require that 503A pharmacies compound using pharmaceutical-grade active pharmaceutical ingredients (API) and meet USP <797> sterile compounding standards for injectable preparations [11].

The practical implication for Delaware patients: a compounding pharmacy producing evolocumab injectable solution can offer the drug at a substantially lower price than the Amgen brand. Cash-pay patients who cannot use the Amgen copay card (for example, Medicare beneficiaries above the income threshold for free drug) may find compounded evolocumab to be the most accessible option financially.

Patients considering compounded evolocumab should ask the pharmacy for its USP <797> accreditation documentation, the source of the API, and the lot-release testing certificate. The prescribing provider should confirm the pharmacy's Delaware licensure status through the Delaware Division of Professional Regulation before sending the prescription [12]. Compounded products are not FDA-approved and do not carry the same labeling guarantees as the brand product, but in a properly accredited pharmacy the biologic activity of the compounded peptide can be verified through third-party potency testing.

Clinical Evidence Behind the Cost: Is Repatha Worth It?

The cost discussion only makes sense with the efficacy data in view. The FOURIER trial (N=27,564 patients with established cardiovascular disease) published in the New England Journal of Medicine in 2017 showed that evolocumab reduced LDL-C by a mean of 59% versus placebo (from a median baseline of 92 mg/dL to 30 mg/dL) at 48 weeks [13]. The primary composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization was reduced by 15% (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001) [13].

The GLAGOV trial (N=968 patients) demonstrated that adding evolocumab to statin therapy produced significant regression of coronary atherosclerosis measured by intravascular ultrasound: 64.3% of evolocumab-treated patients showed plaque regression versus 47.3% of placebo patients [14]. That structural finding supports the mechanistic case for aggressive LDL lowering in high-risk Delaware patients who have already had a cardiac event.

The 2022 ACC/AHA guideline on cholesterol management provides explicit thresholds. For very-high-risk ASCVD patients, the guideline recommends an LDL-C goal of <70 mg/dL and states that PCSK9 inhibitors are appropriate when LDL-C remains above that threshold despite maximally tolerated statin plus ezetimibe [4]. A patient whose LDL-C stays at 90 mg/dL on rosuvastatin 40 mg plus ezetimibe 10 mg fits that criteria exactly and would be a strong candidate for Repatha under both clinical guidelines and Delaware Medicaid PA criteria [3].

The Institute for Clinical and Economic Review (ICER) has assessed PCSK9 inhibitor cost-effectiveness. At the 2026 list price of $580/month, the cost per quality-adjusted life year (QALY) for evolocumab in very-high-risk ASCVD patients exceeds standard cost-effectiveness thresholds, but with net pricing and rebates, the value assessment improves substantially [15]. This economic tension is why insurers require prior authorization: they are attempting to target the drug to the patients whose risk level justifies the expenditure.

Telehealth Prescribing of Repatha in Delaware

Delaware permits telehealth prescribing of Repatha. The Drug Enforcement Administration's telehealth prescribing rules cover only controlled substances; evolocumab is not a controlled substance, so no in-person visit is required under federal law [16]. Delaware's telehealth statute (16 Del. C. § 9603) requires that a valid patient-provider relationship be established and that the standard of care be met, but it does not mandate an in-person exam before prescribing non-controlled medications [17].

In practical terms, a Delaware patient can complete an asynchronous or synchronous telemedicine visit with a licensed Delaware prescriber, provide prior lipid panel results and medical history, and receive a Repatha prescription electronically. The prescriber must review the clinical record and confirm the diagnosis (FH or ASCVD) before prescribing. HealthRX providers follow this workflow for Delaware patients requesting PCSK9 inhibitor therapy.

Insurance prior authorization still applies regardless of whether the prescription comes from a telehealth provider or an in-person physician. The PA submission process is the same, and telehealth providers can submit PA documentation directly to the pharmacy benefit manager. Delaware Medicaid specifically recognizes telehealth-originating prescriptions for covered drugs as long as the treating provider holds a valid Delaware license or is licensed in their home state and treating across state lines under Delaware's Telehealth Compact participation [18].

The Amgen Repatha SupportPlus Savings Card: How It Actually Works

The Amgen SupportPlus program has two tracks. The copay card track is for commercially insured patients. The free-drug track (patient assistance program) is for uninsured or underinsured patients and Medicare beneficiaries who meet income criteria.

For the copay card, the patient must have commercial insurance that covers Repatha. The card pays the gap between the insurance copay or coinsurance and the patient's out-of-pocket responsibility, up to the annual maximum of $7,200 [1]. There is no income requirement for the copay card. Patients with commercial insurance and high deductibles benefit most from the card in the first half of the year, before the deductible is met.

For the free-drug track, income documentation is required. Amgen uses an income threshold based on the federal poverty level, and the threshold has historically been generous, covering patients with household incomes well above the median. A Delaware single-person household with an annual income of $75,000 may still qualify depending on insurance status and the specific program terms in effect for 2026 [1].

Enrollment for both tracks is available at Amgen's website or by calling 1-844-REPATHA. Delaware pharmacies that stock Repatha are familiar with the enrollment process and can often assist patients at the counter. The card reloads each January 1, so patients filling in December should be aware that a January fill may require re-enrollment or card activation for the new year.

Practical Step-by-Step: Getting Repatha at the Lowest Cost in Delaware

Getting to the lowest possible out-of-pocket cost in Delaware follows a clear sequence. First, confirm the clinical diagnosis. A prescriber must document either HeFH (ideally with a Dutch Lipid Clinic Network score or genetic testing) or established ASCVD with documentation of LDL-C above guideline thresholds on maximally tolerated statin therapy [4].

Second, check insurance formulary status. Before the prescriber submits anything, the patient or provider should call the pharmacy benefit manager and ask three questions: Is evolocumab on formulary? What tier? Is a PA required and what are the criteria? This 15-minute call prevents a PA denial based on missing documentation.

Third, submit the PA with complete documentation. Include the most recent lipid panel, the statin dose and duration, any documentation of statin intolerance (CPK levels, symptom diary), the LDL-C goal per guidelines, and a brief clinical summary. Specialists who submit complete documentation on the first attempt have substantially higher first-pass approval rates [5].

Fourth, enroll in the Amgen savings card before the first fill. Go to Amgen's enrollment portal or call the number above. Keep the card number in a digital wallet for easy access at the pharmacy.

Fifth, if commercial insurance denies coverage and the appeal fails, or if the patient is on Medicare above the income threshold for free drug, evaluate 503A compounded evolocumab. Ask the HealthRX clinical team for a referral to an accredited Delaware 503A pharmacy, confirm their USP <797> status, and proceed with a new prescription directed to the compounding pharmacy [11].

LDL-C Monitoring After Starting Repatha

After the first injection, a fasting lipid panel at 4 to 8 weeks confirms the therapeutic response. The FDA-labeled expectation based on FOURIER data is an LDL-C reduction of approximately 59% from baseline [13]. A patient starting at LDL-C 110 mg/dL should reach approximately 45 mg/dL. If the 8-week LDL-C remains above 70 mg/dL in a very-high-risk patient, the prescriber should verify injection technique and adherence before attributing the result to treatment failure.

Evolocumab is generally well tolerated. The most common adverse effects reported in FOURIER were injection-site reactions (2.1% evolocumab vs. 1.6% placebo) and nasopharyngitis [13]. Neurocognitive events were a concern in early trials; the EBBINGHAUS sub-study (N=1,974 FOURIER participants) found no significant difference in cognitive function between evolocumab and placebo across all measured domains over a median follow-up of 19 months [19]. Delaware patients who report memory concerns on PCSK9 inhibitor therapy should be reassured by this data while the prescriber rules out other causes.

Ongoing monitoring should include a lipid panel every 6 to 12 months once at goal, and liver function tests are not routinely required with PCSK9 inhibitors (unlike statins) because the mechanism does not involve hepatic enzyme elevation [20]. Annual reassessment of PA criteria is required for Delaware Medicaid continued authorization [3].